Development of Mithramycin Analogues with Improved Efficacy and Reduced Toxicity for Treatment of ETS-Dependent Tumors in Ewing Sarcoma and Prostate Cancer

Joseph Michael Eckenrode
Introduction: Genetic rearrangements in Ewing sarcoma, prostate, and leukemia cells result in activation of oncogenic ETS transcription factor fusions. Mithramycin (MTM) has been identified as an inhibitor of EWS-FLI1 transcription factor, a gene fusion product responsible for oncogenesis in Ewing sarcoma. Despite preclinical success, a phase I/II clinical trial testing MTM therapy in refractory Ewing sarcoma was terminated. Liver and blood toxicities resulted in dose de-escalation and sub-therapeutic exposures. However, the promise of selectively targeting...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.